The B-MAN Kit’s CELLect filtration technology allows for the efficient collection of bone marrow aspirate. Credit: SurGenTec/Business Wire.

SurGenTec has secured the US Food and Drug Administration’s (FDA) 510(k) clearance for its B-MAN Bone Marrow Aspirate Kit.

The kit features an integrated filtration system that simplifies the collection of high-quality bone marrow aspirate.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The B-MAN Kit’s CELLect filtration technology, coupled with a diamond-tip trocar, allows for the collection of bone marrow aspirate without the need for a centrifuge.

This method not only streamlines the process but also ensures the aspirate is of high quality with minimal contaminants.

Traditionally, bone marrow aspiration can be cumbersome, often requiring centrifugation that can harm cell viability.

SurGenTec’s B-MAN Kit addresses this issue by offering a more efficient and less invasive alternative, which is expected to benefit both healthcare providers and patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The kit’s design allows for increased contact with bone marrow, enhancing the retrieval of progenitor cells and reducing contamination.  

SurGenTec CEO Travis Greenhalgh said: “We are excited to add this unique device to our product portfolio. Our aim was to create a minimally invasive solution that simplifies the aspiration process while optimising cell quality.

“The B-MAN Kit preserves native cell structure and facilitates the extraction of healthier cells by reducing the manipulation that takes place, providing physicians with a robust autologous option for patient treatment.”

SurGenTec’s B-MAN Kit provides a safer option for cell-based therapies by using the patient’s own cells, thus reducing the risk of disease transmission associated with donor-derived products.